The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 19, 2023

Filed:

Jan. 14, 2022
Applicant:

Erimos Pharmaceuticals, Llc, Houston, TX (US);

Inventors:

Jeffrey Khoo, Singapore, SG;

Stephan D. Glenn, Weston, FL (US);

Assignee:

Erimos Pharmaceuticals, LLC, Houston, TX (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/09 (2006.01); A61P 31/14 (2006.01); A61K 31/05 (2006.01);
U.S. Cl.
CPC ...
A61K 31/09 (2013.01); A61K 31/05 (2013.01); A61P 31/14 (2018.01);
Abstract

Nordihydroguaiaretic acid (NDGA) derivatives, including terameprocol (TMP) have utility as anti-viral agents for use on patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. In vitro studies show coronavirus-infected cells treated with 0.2 μM-20 μM TMP show reduced viral RNA activity in vitro. Treatment-related cytotoxicity is not shown at 0.2 μM TMP with a low percentage of cytotoxicity shown at 5 μM TMP. In application, the NDGA derivatives may be administered to a patient intravenously at a molar concentration of 0.1-50 μM or orally at a molar concentration of 0.1-100 μM.


Find Patent Forward Citations

Loading…